US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Mereo BioPharma Group PLC (MREO)
Mereo BioPharma Group PLC (MREO) Noticias

MREO

Mereo BioPharma (MREO)

Mereo BioPharma Group PLC

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MREO

1 2 3 4 5 6 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
15/05/2024	15:49	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:MREO	Mereo BioPharma Group PLC
15/05/2024	15:19	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MREO	Mereo BioPharma Group PLC
15/05/2024	15:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MREO	Mereo BioPharma Group PLC
15/05/2024	15:01	GlobeNewswire Inc.	Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:MREO	Mereo BioPharma Group PLC
03/04/2024	06:30	GlobeNewswire Inc.	Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:MREO	Mereo BioPharma Group PLC
27/03/2024	15:01	GlobeNewswire Inc.	Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:MREO	Mereo BioPharma Group PLC
05/03/2024	06:30	GlobeNewswire Inc.	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference	NASDAQ:MREO	Mereo BioPharma Group PLC
09/02/2024	15:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MREO	Mereo BioPharma Group PLC
06/02/2024	15:15	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MREO	Mereo BioPharma Group PLC
23/01/2024	15:16	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:MREO	Mereo BioPharma Group PLC
08/01/2024	06:00	GlobeNewswire Inc.	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments	NASDAQ:MREO	Mereo BioPharma Group PLC
02/01/2024	15:20	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MREO	Mereo BioPharma Group PLC
18/12/2023	15:16	Edgar (US Regulatory)	Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]	NASDAQ:MREO	Mereo BioPharma Group PLC
18/12/2023	15:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MREO	Mereo BioPharma Group PLC
23/10/2023	15:01	GlobeNewswire Inc.	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update	NASDAQ:MREO	Mereo BioPharma Group PLC
14/10/2023	15:30	GlobeNewswire Inc.	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)	NASDAQ:MREO	Mereo BioPharma Group PLC
09/10/2023	07:00	GlobeNewswire Inc.	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)	NASDAQ:MREO	Mereo BioPharma Group PLC
21/09/2023	06:00	GlobeNewswire Inc.	Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference	NASDAQ:MREO	Mereo BioPharma Group PLC
07/09/2023	06:30	GlobeNewswire Inc.	Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update	NASDAQ:MREO	Mereo BioPharma Group PLC
26/07/2023	15:31	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:MREO	Mereo BioPharma Group PLC
06/07/2023	07:00	GlobeNewswire Inc.	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)	NASDAQ:MREO	Mereo BioPharma Group PLC
16/06/2023	07:00	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:MREO	Mereo BioPharma Group PLC
05/06/2023	15:38	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:MREO	Mereo BioPharma Group PLC
31/05/2023	06:00	GlobeNewswire Inc.	Mereo BioPharma to Present at the Jefferies Healthcare Conference	NASDAQ:MREO	Mereo BioPharma Group PLC
23/05/2023	12:43	GlobeNewswire Inc.	Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference	NASDAQ:MREO	Mereo BioPharma Group PLC
08/05/2023	11:46	GlobeNewswire Inc.	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:MREO	Mereo BioPharma Group PLC
05/05/2023	15:06	GlobeNewswire Inc.	Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market	NASDAQ:MREO	Mereo BioPharma Group PLC
13/04/2023	07:00	GlobeNewswire Inc.	Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference	NASDAQ:MREO	Mereo BioPharma Group PLC
28/03/2023	15:30	GlobeNewswire Inc.	Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights	NASDAQ:MREO	Mereo BioPharma Group PLC
21/03/2023	05:30	GlobeNewswire Inc.	Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease	NASDAQ:MREO	Mereo BioPharma Group PLC

Showing the most relevant articles for your search:NASDAQ:MREO

1 2 3 4 5 6 Próxima >

Dongyang Express

Noble Metal (CE)

Costa Rica 54 A

GDF Suez 2.375% 2026

DAXsubsector All Softwar...

GS Finance Corp. Capped ...

BBASJ437 Ex:21,34

IQ Mackay ESG High Incom...

KH Neochem (PK)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones